Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012)

Galectin Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $200000.0 for Q2 2012.

• In Q2 2012, Current Deferred Revenue changed 0.0% year-over-year to $200000.0; the TTM figure through Jun 2012 stood at $200000.0 (changed 0.0% YoY), while the FY2011 annual figure was $200000.0, changed 0.0% from the prior year.
• Current Deferred Revenue was $200000.0 for Q2 2012 at Galectin Therapeutics, roughly flat from $200000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $200000.0 in Q4 2010 to a low of $200000.0 in Q4 2010.
• Historically, Current Deferred Revenue has averaged $200000.0 across 3 years, with a median of $200000.0 in 2010.
• Biggest YoY gain for Current Deferred Revenue was 0.0% in 2011; the steepest drop was 0.0% in 2011.
• A 3-year view of Current Deferred Revenue shows it stood at $200000.0 in 2010, then changed by 0.0% to $200000.0 in 2011, then changed by 0.0% to $200000.0 in 2012.
• The last three Current Deferred Revenue figures came in at $200000.0 (Q2 2012), $200000.0 (Q1 2012), and $200000.0 (Q4 2011), per Business Quant data.